NYSE: DGX · Diagnostics & Research

Quest Diagnostics (DGX) fair value: undervalued or overvalued?

As of 15 Nov 2026, Faircurve's model values Quest Diagnostics (DGX) at $314.32 a share. The stock last closed at $262.21, which puts the model's fair value 19.9% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 16 Nov 2026. Quest Diagnostics Incorporated.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$314.32midpoint of 2,000 simulations
Last close$262.21NYSE: DGX
Gap to fair value+19.9%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 15 Nov 2026 moved the fair value from $302.79 to $314.32 (+3.8%).

What the model makes of itThe price of $262.21 is 19.9% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 9 Feb 2027. Options prices imply a move of about 8% either way over the next month. On the model's Scorecard Leaders list since 4 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give DGX?

The calibrated range for DGX over 63 trading days is $240.27 to $287.42. It sits around the last close, and its width comes from the volatility that DGX's own options imply (26% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $248.07 to $386.54. In 75% of the simulations the fair value came out above the price the model ran on.

$182.25$526.34
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $314.32. Dashed line: the last close, $262.21.

Faircurve Insights · 15 Nov 2026

Quest Diagnostics Incorporated (DGX) is a premier provider of diagnostic testing, information and related services. It was founded in 1967 and is headquartered in Secaucus, New Jersey, serving clients both domestically and internationally.

Faircurve's model gives Quest Diagnostics a fair value of $314.32 a share on 15 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $302.79, so the model's fair value moved +3.8%. The calibrated range over 63 trading days is $235.83 to $287.15. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices: 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

Quest Diagnostics scores 74 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Earnings quality is the strongest, at 90, with free cash flow at 1.22x net income. Stability scores 87, with five-year EBITDA margin downside volatility of 1.9 pts against a peer median of 11.4 pts. The balance sheet scores 42, with net debt at 2.38x EBITDA. The model compares the company with Illumina, Mettler-Toledo, IQVIA, Medpace, Waters, Revvity and Agilent. Labcorp is also a comparable company, but it has no verdict on this date.

Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does DGX report earnings, and how has the stock reacted?

Quest Diagnostics's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 6.2% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. DGX's 30 day implied volatility works out to about 7.6% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DGX's last 8 reports, ignoring direction, was 4.4%.

0%5%10%7.4%7.2%22 Apr '256.2%2.4%22 Jul '256.6%4.9%21 Oct '255.1%9.4%10 Feb '266.6%3.9%21 Apr '267.5%8.6%23 Jul '267.6%1.7%20 Oct '269.6%1.2%22 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in DGX

0%5%10%15%22 Oct '26 report20 Oct '26 report23 Jul '26 report21 Apr '26 report10 Feb '26 report8% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 7% on 14 Nov 2025, reached 11% on 23 Sep 2026 and reads 8% on 16 Nov 2026. The marks are report dates.

How does DGX score on business quality?

Quest Diagnostics's overall quality score is 74 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.759.9%ROIC-12.5%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).901.22xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.7011.8%Revenue growth, trailing20.1%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.631.9%Net buybacks / market value0.9%
Balance sheetNet debt to EBITDA and interest coverage.422.38xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.871.9 ptsEBITDA margin downside volatility, 5y11.4 pts

How does DGX compare with similar companies?

The companies in diagnostics & research closest to Quest Diagnostics in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
LH Labcorp Holdings Inc.$372.46$465.68+25.0%Low evidence grade
ILMN Illumina, Inc.$198.00$172.96-12.6%Fairly valued
MTD Mettler-Toledo International Inc.$1,727.26$1,679.36-2.8%Fairly valued
IQV IQVIA Holdings Inc.$264.73$335.69+26.8%Undervalued
MEDP Medpace Holdings, Inc.$648.20$717.73+10.7%Fairly valued
WAT Waters Corporation$453.42$337.75-25.5%Overvalued
RVTY Revvity, Inc.$148.85$185.05+24.3%Undervalued
A Agilent Technologies, Inc.$172.92$176.09+1.8%Fairly valued

What the comparable companies' multiples alone would give for DGX, the peer-implied price, is $1,477.66 a share on this run. The fair value weighs that against the company's own multiple.

All diagnostics & research stocks ranked by gap to fair value

Quest Diagnostics at a glance

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally.

Market value
$28.6B
Sector
Healthcare
Industry
Diagnostics & Research
Revenue expected, next twelve months
$12.6B
Consensus revenue growth, next fiscal year
+9.5%
Analysts with estimates
11
Beta to the US market
-0.13
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. DGX was among them.

How the fair value is worked out: the model prices Quest Diagnostics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for DGX was $302.79. As of 15 Nov 2026 it is $314.32, a change of +3.8%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Quest Diagnostics's valuation

Is Quest Diagnostics stock undervalued or overvalued?

On Faircurve's model, DGX reads as Undervalued as of 15 Nov 2026. The model's fair value is $314.32 a share against a last close of $262.21, a gap of +19.9%.

What is DGX's fair value?

$314.32 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $248.07 to $386.54.

What price range does the model give DGX?

$240.27 to $287.42 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Quest Diagnostics report earnings next?

The next report is scheduled for 9 Feb 2027. Companies can move their dates.

How much has DGX moved on past earnings reports?

Across its last 8 reports the median two session move was 4.4%, ignoring direction. The largest was +9.4% around the report of 10 Feb 2026.

How confident is the model in this valuation?

The model's evidence grade for DGX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on DGX

The model has an idea open on DGX under Scorecard Leaders since 4 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DGX with their outcomes. A free account is enough.

Keep reading